Skip to main content
Download PDF

The prevalence of low muscle mass associated with obesity in the USA

Skeletal Muscle volume 12, Article number: 26 (2022) Cite this article

Abstract

Background

Sarcopenia is defined as age-related low muscle mass and function, and can also describe the loss of muscle mass in certain medical conditions, such as sarcopenic obesity. Sarcopenic obesity describes loss of muscle and function in obese individuals; however, as sarcopenia is an age-related condition and obesity can occur in any age group, a more accurate term is obesity with low lean muscle mass (OLLMM). Given limited data on OLLMM (particularly in those aged < 65 years), the purpose of this study was to estimate the prevalence of OLLMM in adults aged ≥ 20 years in the USA.

Methods

Data from the National Health and Nutrition Examination Survey (NHANES) 2017–2018 and 1999–2006 were used. OLLMM was defined as an appendicular lean mass, adjusted for body mass index (BMI), cut-off point < 0.789 for males and < 0.512 for females, measured by dual-energy X-ray absorptiometry (DXA). DXA was only measured in individuals 20–59 years old in NHANES 2017–2018; we therefore utilized logistic regression models to predict OLLMM from NHANES 1999–2006 for those aged ≥ 60 years. The prevalence of OLLMM was estimated overall, and by sex, age, race/ethnicity, and clinical subgroup (high BMI, prediabetes, type 2 diabetes mellitus [T2DM], non-alcoholic fatty liver disease [NAFLD] with fibrosis, or post-bariatric surgery). Prevalence estimates were extrapolated to the USA population using NHANES sampling weights.

Results

We estimated that, during 2017–2018, 28.7 million or 15.9% of the USA population had OLLMM. The prevalence of OLLMM was greater in older individuals (8.1%, aged 20–59 years vs 28.3%, aged ≥ 60 years), highest (66.6%) in Mexican-American females aged ≥ 60 years, and lowest (2.6%) in non-Hispanic Black males aged 20–59 years. There was a higher prevalence of OLLMM in adults with prediabetes (19.7%), T2DM (34.5%), NAFLD with fibrosis (25.4%), or post-bariatric surgery (21.8%), compared with those without each condition.

Conclusions

Overall, the burden of OLLMM in the USA is substantial, affecting almost 30 million adults. The prevalence of OLLMM increased with age, and among those with prediabetes, T2DM, NAFLD with fibrosis, or post-bariatric surgery. A unified definition of OLLMM will aid diagnosis and treatment strategies.

Background

The prevalence of obesity is increasing globally, with numbers doubling in more than 70 countries since 1980 [1]. Among children and adolescents, the prevalence of obesity has more than tripled since the 1970s [2, 3]. These dramatic increases in prevalence have led to a rise in obesity-associated comorbidities [4].

Sarcopenia, defined as loss of skeletal muscle mass and function in older people [5] has recently been classified as a muscle disease, and is diagnosed based on an assessment of muscle mass, strength, and anthropometric measures [6,7,8,9]. The term sarcopenia has also been used to denote loss of muscle due to a particular clinical comorbidity; for example “sarcopenic obesity,” which describes muscle loss in obese individuals [10, 11]. However, since the term sarcopenia is considered age-related and obesity can occur at any age, we proposed using the term obesity with low lean muscle mass (OLLMM) to describe this phenomenon across all age groups. OLLMM has been proposed to occur as a result of mechanistic inflammatory signaling, activin, and metabolic syndrome pathway activation by adipose-produced cytokines, ultimately increasing catabolism of lean muscle [12,13,14]. It is characterized by the co-existence of reduced muscle mass and excess fat mass. Although OLLMM can occur at any age, it is more common in older adults [15]. Both obesity and sarcopenia are independently associated with chronic cardiovascular diseases and diabetes [16, 17]. Loss of muscle in obese individuals has been linked to increased insulin resistance, risk of type 2 diabetes mellitus (T2DM), disability, morbidity, and mortality [16, 18,19,20,21]. Sarcopenia has been associated with insulin resistance, liver fibrosis [22, 23], frailty, and mortality [24]. Sarcopenia and obesity both display distinct and common pathophysiological features, which may act synergistically [16, 18] to increase the risk of developing adverse health issues. Consequently, people with both sarcopenia and obesity are an especially vulnerable population. Therefore, it is important to identify affected individuals and understand the factors that could contribute to morbidity within this population [19].

Historically, the prevalence of sarcopenic obesity has been difficult to assess, due to the unclear and confusing nature of the term, as well as a paucity of data for younger age groups. As such, prevalence estimates vary dramatically between different studies due to heterogeneity in the definitions of sarcopenia and obesity, as well as the populations assessed [25, 26]. Previous prevalence estimates of sarcopenic obesity in the USA, obtained from National Health and Nutrition Examination Survey (NHANES) data, are limited. Several of the prior estimates rely on data roughly 20 years old [27,28,29]. Additionally, the estimate using more recent data (NHANES 2017–2018) does not include participants aged > 59 years, thus excluding the population at the highest risk for sarcopenic obesity [30].

The lack of a standard definition makes the condition difficult to diagnose (impacting prevalence estimates and development of treatment strategies) and can result in mixed populations in clinical trials [6, 15, 31]. A consensus on diagnostic tools and criteria is needed, as well as identification of optimal prevention and treatment options [32]. The objective of this study was to estimate the prevalence of low muscle mass in obese individuals (previously known as sarcopenic obesity), in USA adults aged ≥ 20 years. Additionally, we assessed how the prevalence of OLLMM differed by age, race/ethnicity, high-risk clinical subgroups, and body mass index (BMI) categories.

Methods

Data sources and analytic sample

A cross-sectional multi-step analysis was performed using data from NHANES 1999–2006 and 2017–2018. The analytic sample included all survey participants who were aged ≥ 20 years. NHANES uses a complex, multistage probability sampling design to select participants representative of the non-institutionalized USA population, and collects demographic, socioeconomic, dietary, and health-related data. Further details of the NHANES methods and analytic guidelines are described elsewhere [33].

Measurement and definition of OLLMM

Dual-energy X-ray absorptiometry (DXA) measurements (bone and soft tissue) of body composition for survey participants have been collected as part of the NHANES study since 1999. DXA is considered a robust and reproducible way of measuring components of body composition, including bone density, body fat (BF) percentage, and appendicular lean mass (ALM) [6]. In the 2017–2018 survey, DXA data were available for participants aged 20–59 years. BMI was calculated from height and weight measurements, which were collected by trained health technicians and were available for all ages. In order to determine OLLMM in participants ≥ 60 years of age, data from prior years of NHANES were used, when DXA was measured across a wider range of ages (i.e., ages ≥ 8 years in 1999–2004, and ages 8–69 years in 2005–2006), to construct models predicting OLLMM among those aged ≥ 60 years in the 2017–2018 dataset described in detail below.

OLLMM was defined using the Foundation for the National Institutes of Health (FNIH) criteria for low lean mass associated with weakness (ALM adjusted for BMI, cut-off point for males < 0.789 and for females < 0.512) [34, 35], and the American Association of Clinical Endocrinology BF percentage thresholds for the diagnosis of obesity (males > 25% and females > 35%) [36].

Predicting OLLMM and sarcopenia in patients aged ≥ 60 years

For individuals aged ≥ 60 years, OLLMM status was predicted using an algorithm, modeled using various measures based on the 1999–2006 NHANES data, and then applied to the 2017–2018 NHANES data. The sensitivity analysis defined OLLMM based on ALM and BMI ≥ 27 kg/m2 [36]. A BMI of ≥ 27 kg/m2 was chosen to define OLLMM, as it is the minimum BMI threshold recommended for intervention with anti-obesity medications by the Obesity Society, the Endocrine Society, and the American Association of Clinical Endocrinologists [36,37,38].

Definition of other measures

Participants were stratified (Supplemental Table S1) by high BMI (class 1: BMI 30 to < 35 kg/m2, class 2: BMI 35 to < 40 kg/m2, class 3: BMI ≥ 40 kg/m2); prediabetes (based on glycated hemoglobin ≥ 5.7% to < 6.5%, or if the participant responded yes to the question “Have you ever been told by a doctor or other health professional that you have any of the following: prediabetes, impaired fasting glucose, impaired glucose tolerance, or borderline diabetes, or that your blood sugar is higher than normal but not high enough to be called diabetes or sugar diabetes?”); T2DM (based on glycated hemoglobin ≥ 6.5%, or answered yes to “Other than during pregnancy, have you ever been told by a doctor or health professional that you have diabetes or sugar diabetes?”), excluding those who reported insulin therapy only or were diagnosed with diabetes aged < 30 years [39]; non-alcoholic fatty liver disease (NAFLD) with fibrosis (based on median controlled attenuated parameter of > 285 dB/m, and liver stiffness of ≥8 kPa [excluding those with excessive alcohol consumption determined using self-reported average number of alcohol drinks/day over the past 12 months]); and history of bariatric surgery (based on those who answered yes to “Have you ever had weight loss surgery?”).

Statistical analysis

Descriptive analyses of baseline characteristics and outcome variables were performed. Median values (25th and 75th percentile) are presented for continuous outcomes. Frequency, weighted frequency, and weighted proportion (95% confidence intervals [CIs]) are presented for categorical measures.

The NHANES 1999–2006 data were split into a 70% training sample and a 30% testing sample. Logistic regression was used to create age (< 60 and ≥ 60 years) and sex-specific models utilizing the training sample, as the mechanism and predictors were expected to be different. Backward stepwise selection was used to identify potential predictors, such as demographics (age, sex, race/ethnicity, region), comorbidities, anthropometric measures, laboratory results, and physical performance measures were identified from prior literature. Variables that were consistently significant (p < 0.1) across different models were selected for the final model. Performance of the fitted models was tested on the 30% validation sample. The area under the receiver operating characteristic curve (AUC) was calculated to evaluate the model performance in the training and testing samples. Once a high-performing model was selected, it was used to predict the likelihood that an individual (aged ≥ 60 years) in the 2017–2018 survey year had OLLMM. For further details on model performance, please see the Supplementary material and Supplemental Table S2.

Data were analyzed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Survey procedures were used to account for the complex NHANES survey design, the sampling weights and non-response. Prevalence was estimated based on the number of cases of OLLMM identified via DXA (patients aged 20–59 years) or the classification model (patients aged > 60 years). Analytical methods accounting for multiple imputing and combined sampling weight across the four waves of data were used when analyzing NHANES 1999–2006 data [40].

Results

A total of 9254 participants were included in the 2017–2018 NHANES survey; 4174 of those were ≥ 20 years and eligible for this study. Of the individuals included, 2156 (weighted percentage 61.6%) were aged 20–59 years with DXA scans, and 2018 (weighted percentage 38.4%) were aged ≥ 60 years with predicted OLLMM status (Table 1). Approximately half the participants were female (2118, 52.0%). Sample sizes within each age and race/ethnic group are listed in Table 1. The prediction model was developed using data from 4889 participants aged ≥ 60 years from the 1999–2006 NHANES database (see Supplementary material), and model performance for OLLMM was excellent for both males and females aged ≥ 60 years, with an AUC of 0.91 and 0.87, respectively (Supplemental Figures S1 and S2, and Supplemental Table S2).

Table 1 Prevalence of OLLMM in different groups (based on percentage BF)
Full size table

Overall prevalence

Of the 4174 participants who were included in the study (representing 181,176,597 individuals aged ≥ 20 years in the USA), 827 (representing 28,728,420 individuals) were classified as having OLLMM, either using the prediction model for those aged ≥ 60 years or directly from the 2017–2018 NHANES data for those aged 20–59 years. The overall prevalence of OLLMM was estimated at 15.9% (95% CI, 13.7–18.0%) of the USA population (Table 1).

Prevalence of OLLMM by sex, age group, and race

The prevalence of OLLMM was 16.4% (95% CI, 14.0–18.8%) and 15.3% (95% CI, 12.3–18.2%) in females and males, respectively (Table 1). Prevalence of OLLMM increased with each decade of life starting as low as 5.1% in those aged 20–29 years and increasing to 38.7% among those aged ≥80 years (Table 1). When stratified by 20–59 and ≥ 60 years of age, the prevalence of OLLMM was greater in those aged ≥ 60 years (8.1% of those aged 20–59 years vs 28.3% of those aged ≥ 60 years). Additionally, compared with non-Hispanic Whites, OLLMM was higher in Mexican-Americans and other Hispanic ethnic groups (27.0%; 95% CI, 22.7–31.3%, and 21.1%; 95% CI, 16.4–25.7%, respectively), and lowest in non-Hispanic Black groups (3.7%; 95% CI, 2.5–5.0%; Table 1). Furthermore, in analyses stratified by age, sex, and race/ethnicity, the highest prevalence of OLLMM (66.6%; 95% CI, 59.8–73.4%) was found among Mexican-American females aged ≥ 60 years and the lowest prevalence (2.6%; 95% CI, 1.1–4.0%) was found in non-Hispanic Black males aged 20–59 years (Table 2).

Table 2 Prevalence of OLLMMa by age, sex, and race/ethnicity (based on percentage BF)
Full size table

Prevalence of OLLMM by clinical subgroups and BMI

The prevalence of OLLMM was higher in people with the following clinical conditions/procedures compared with those without: T2DM (34.5% vs 12.7%), prediabetic (19.7% vs 14.7%), those diagnosed with NALFD with fibrosis (25.4% vs 12.5%), or in those who had undergone bariatric surgery (21.8% vs 15.8%; Table 3). Additionally, we found that the prevalence of OLLMM increased as BMI increased, with 9.2% (95% CI, 7.8–10.6%) of those with BMI < 30 kg/m2 having OLLMM compared with 35.0% (95% CI, 26.1–43.9%) of those with BMI ≥ 40 kg/m2.

Table 3 Prevalence of OLLMM in different clinical subgroups (based on percentage BF)
Full size table

Characteristics of individuals with OLLMM

Among those with OLLMM, the majority were female (53.8%; 95% CI, 48.3–59.3%) and most (64.6%; 95% CI, 56.5–72.7%) were non-Hispanic White (Supplemental Table S3). The median age was higher among those with OLLMM at 65.2 years (interquartile range [IQR] 54.9–74.8) compared with 47.9 years (IQR 32.6–62.5) in those without OLLMM. Median BMI and waist circumference were higher in those with OLLMM compared with: those without 32.6 kg/m2 (IQR 28.6–36.3) and 108.9 cm (IQR 100.0–118.9) versus 27.4 kg/m2 (IQR 23.7–31.7), and 96.2 cm (IQR 85.7–107.4), respectively (Supplemental Table S3).

Comorbidities and general health were also associated with the prevalence of OLLMM. The prevalence of comorbidities, including high blood pressure or high cholesterol level, tended to be higher among those with OLLMM compared with those without (Fig. 1). A higher percentage of people with OLLMM reported poor or fair general health compared with those without OLLMM (Table 4). Across all age groups, those with OLLMM tended to have more physical limitations, with a higher percentage reporting limitations in stooping, crouching, kneeling, or standing for long periods (Supplemental Table S4).

Fig. 1
figure 1

Comorbidities in participants with and without OLLMM (based on percentage BF). BF, body fat; OLLMM, obesity with low lean muscle mass

Full size image
Table 4 General health and clinical recommendations for participants with or without OLLMM (based on percentage BF)
Full size table

Sensitivity analysis

When using BMI ≥ 27 kg/m2 to define obesity instead of percentage BF, combined with the definition of low lean muscle mass, fewer cases of OLLMM (n = 671, representing 23,934,214 individuals) were identified. Among the OLLMM cases identified by percentage BF criteria, only 80.3% met the criteria of low lean muscle mass and BMI ≥ 27 kg/m2. However, 96.4% of OLLMM cases identified using BMI were also identified based on the percentage BF criteria. Overall, 83.7% of people did not meet either of the criteria for OLLMM (weighted n = 151,575,945; n = 3307).

The prevalence of OLLMM in the sensitivity analysis was lower with an estimated 13.2% of the USA population (23,934,214 people) during 2017–2018 having OLLMM (Supplemental Figure S3). Although the estimates were consistently lower than the primary analysis, similar trends in the prevalence of OLLMM by sex, age, race/ethnicity, and clinical conditions/procedures were observed in the sensitivity analysis.

Discussion

Global prevalence estimates of sarcopenic obesity are wide-ranging due to heterogeneity in definitions for sarcopenia and obesity, their measurements, and the populations assessed [6, 15, 25, 26, 31]. By using OLLMM as a standard term and providing clear criteria for both obesity and “low lean muscle mass,” the prevalence of this serious condition was estimated and also stratified across younger adult (aged ≥ 20 years) and elderly (aged ≥ 70 years) age groups, and across BMI classes. Overall, the prevalence of OLLMM was high in the USA, particularly in older age groups. Participants with a higher BMI, prediabetes, T2DM, post-bariatric surgery, or NAFLD with fibrosis had a higher risk of OLLMM, regardless of age.

The prevalence of OLLMM was estimated using 2017–2018 NHANES data for all adults aged ≥ 20 years. Prevalence estimates were determined using either percentage BF or BMI to define obesity. Both definitions found consistent patterns by age, although OLLMM prevalence estimates based on BMI ≥ 27 kg/m2 were lower than estimates based on percentage BF, which is consistent with previous studies [28, 29]. This is possibly due to a lack of sensitivity of BMI to reflect an individual's actual percentage BF. Therefore, estimates using BMI rather than percentage BF may underestimate the prevalence of OLLMM, with greater disparity observed in older populations. Compared with previous prevalence estimates using NHANES data from prior survey years in those aged 20–59 years (ranged from 3.3–5.5% [27, 29]) and ≥ 60 years (ranged from 7.0–27.3% [28, 29, 41]), our estimates were generally higher [27,28,29]. This may be due to an increase in the overall prevalence of disease, variability in the definition, or greater sensitivity of the methodology used in this analysis. The change in prevalence of OLLMM from 1999–2006 to 2017–2018, an increase of 5.5% since 1999–2006 [41], may reflect changes in lifestyle (including diet and physical activity) over time, as well as an overall increase in aging and obese populations since the 1999–2006 NHANES USA study.

Prevalence of OLLMM was consistently higher in participants with T2DM, prediabetes, post-bariatric surgery, and NAFLD with fibrosis. OLLMM prevalence also increased with increasing BMI. These findings are expected and comparable to previous studies, which found higher prevalence in those with a higher BMI, T2DM [16, 42, 43], or NAFLD [30]. Additionally, our findings support prior research highlighting the important role of low muscle mass as a risk factor for metabolic disease in participants with chronic diseases, such as diabetes and chronic kidney disease [16, 44, 45]. Furthermore, the presence of OLLMM may occur as a result of increased inflammation, insulin resistance, and decreased anabolic hormones, all of which are associated with both obesity and low muscle mass [46,47,48]. In those aged < 60 years, low lean muscle mass was also associated with an increased risk of dysglycemia in both non-obese and obese individuals. In younger as well as in older adults, low lean muscle mass was also much more prevalent in obese than in non-obese individuals [16]. Therefore, with the global rise in obesity, particularly in children and young adults, our data highlight the increasing age-related prevalence of OLLMM, starting in young adulthood. Interventions aimed at increasing muscle mass in younger ages and preventing loss of muscle mass in older ages, such as activin type II receptor antagonists (e.g., bimagrumab), may have the potential to reduce body fat and improve glycemic control in obese individuals, and thus reduce the risk of T2DM [16, 19, 49].

In other clinical settings, including cachexia, low muscle mass has been shown to dramatically increase the risk of mortality and morbidity, even above the pre-existing serious clinical condition [50]. In those aged 70–79 years, sarcopenia or loss of muscle function have been shown to cause a decrease in walking speed, which itself increases mortality/morbidity due to falls and other mobility-related incidences [51]. Thus, in the future it is vital to determine whether low lean muscle mass increases morbidity or mortality in individuals with obesity.

One limitation of the study is the cross-sectional nature of the data, so inferences regarding an increased risk of OLLMM in certain subgroups cannot be made and are outside of the scope of this analysis. Another limitation was the lack of available DXA measures for the age group ≥ 60 years in the 2017–2018 NHANES survey; however, using modeling techniques we were able to estimate the prevalence in this population. The OLLMM definition used in this study relies on body composition; however, several working groups suggest including a measure of strength or function in defining sarcopenia for future studies. We were unable to include this type of measure as it is not included in the most recent version of NHANES. However, the DXA measures of body composition used are robust, whereas measures of strength and function may be less accurate as they are related to the individual’s motivation, and the level of physical activity decreases in older age groups [52]. Furthermore, the FNIH cut points used in this study were previously derived from large clinical datasets such that the cut points discriminated the presence or absence of weakness and slow gait speed [35, 53].

Conclusions

The prevalence of OLLMM in the USA is higher than previously reported. Individuals with a higher BMI, prediabetes, T2DM, post-bariatric surgery, or NAFLD with fibrosis have a higher risk of OLLMM, regardless of age. A unified definition of OLLMM will help define populations for future clinical trials, especially those aiming to understand the risk of sarcopenia in individuals with obesity, as well as aiding in diagnosis and development of treatment strategies [54]. Clinicians should monitor patients in high-risk clinical groups for OLLMM to facilitate early intervention.

Availability of data and materials

Publicly available datasets were analyzed in this study. These data can be found at https://www.cdc.gov/nchs/nhanes/index.htm

Abbreviations

ALM:

Appendicular lean mass

AUC:

Area under the curve

BF:

Body fat

BMI:

Body mass index

CI:

Confidence interval

DXA:

Dual-energy X-ray absorptiometry

FNIH:

Foundation of National Institutes of Health

IQR:

Interquartile range

NAFLD:

Non-alcoholic fatty liver disease

NHANES:

National Health and Nutrition Examination Survey

OLLMM:

Obesity with low lean muscle mass

ROC:

Receiver operating characteristic

T2DM:

Type 2 diabetes mellitus

USA:

United States of America

References

  1. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27. https://doi.org/10.1056/NEJMoa1614362.

    Article  Google Scholar 

  2. World Health Organization. Obesity and overweight; 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 10 Feb 2022

    Google Scholar 

  3. Fryar CD, Carroll MD, Ogden CL. Prevalence of overweight, obesity, and severe obesity among children and adolescents aged 2–19 years: United States, 1963–1965 through 2015–2016; 2018. https://www.cdc.gov/nchs/data/hestat/obesity_child_15_16/obesity_child_15_16.pdf. Accessed 8 Mar 2022

    Google Scholar 

  4. Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33(7):673–89. https://doi.org/10.1007/s40273-014-0243-x.

    Article  Google Scholar 

  5. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990S–1S. https://doi.org/10.1093/jn/127.5.990S.

    Article  CAS  Google Scholar 

  6. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. https://doi.org/10.1093/ageing/afy169.

    Article  Google Scholar 

  7. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56. https://doi.org/10.1016/j.jamda.2011.01.003.

    Article  Google Scholar 

  8. Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by special interest groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr. 2010;29(2):154–9. https://doi.org/10.1016/j.clnu.2009.12.004.

    Article  CAS  Google Scholar 

  9. Cao L, Morley JE. Sarcopenia is recognized as an independent condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) code. J Am Med Dir Assoc. 2016;17(8):675–7. https://doi.org/10.1016/j.jamda.2016.06.001.

    Article  Google Scholar 

  10. Khadra D, Itani L, Tannir H, et al. Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: a systematic review and meta-analysis. World J Diabetes. 2019;10(5):311–23. https://doi.org/10.4239/wjd.v10.i5.311.

    Article  Google Scholar 

  11. Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15(3):321–35. https://doi.org/10.1159/000521241.

    Article  Google Scholar 

  12. Schrager MA, Metter EJ, Simonsick E, et al. (2007) Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol. 1985;102(3):919–25. https://doi.org/10.1152/japplphysiol.00627.2006.

    Article  Google Scholar 

  13. Correa-de-Araujo R, Addison O, Miljkovic I, et al. Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the National Institute on Aging. Front Physiol. 2020;11:963. https://doi.org/10.3389/fphys.2020.00963.

    Article  Google Scholar 

  14. Rubio-Ruiz ME, Guarner-Lans V, Perez-Torres I, Soto ME. Mechanisms underlying metabolic syndrome-related sarcopenia and possible therapeutic measures. Int J Mol Sci. 2019;20(3):647. https://doi.org/10.3390/ijms20030647.

    Article  CAS  Google Scholar 

  15. Donini LM, Busetto L, Bauer JM, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr. 2020;39(8):2368–88. https://doi.org/10.1016/j.clnu.2019.11.024.

    Article  Google Scholar 

  16. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and nutrition examination survey III. PLoS One. 2010;5(5):e10805. https://doi.org/10.1371/journal.pone.0010805.

    Article  CAS  Google Scholar 

  17. Farmer RE, Mathur R, Schmidt AF, et al. Associations between measures of sarcopenic obesity and risk of cardiovascular disease and mortality: a cohort study and Mendelian randomization analysis using the UK biobank. J Am Heart Assoc. 2019;8(13):e011638. https://doi.org/10.1161/JAHA.118.011638.

    Article  Google Scholar 

  18. Atkins JL, Whincup PH, Morris RW, et al. Sarcopenic obesity and risk of cardiovascular disease and mortality: a population-based cohort study of older men. J Am Geriatr Soc. 2014;62(2):253–60. https://doi.org/10.1111/jgs.12652.

    Article  Google Scholar 

  19. Roh E, Choi KM. Health consequences of sarcopenic obesity: a narrative review. Front Endocrinol (Lausanne). 2020;11:332. https://doi.org/10.3389/fendo.2020.00332.

    Article  Google Scholar 

  20. Baumgartner RN, Wayne SJ, Waters DL, et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res. 2004;12(12):1995–2004. https://doi.org/10.1038/oby.2004.250.

    Article  Google Scholar 

  21. Sayer AA, Syddall HE, Martin HJ, et al. Is grip strength associated with health-related quality of life? Findings from the Hertfordshire cohort study. Age Ageing. 2006;35(4):409–15. https://doi.org/10.1093/ageing/afl024.

    Article  Google Scholar 

  22. Lee YH, Jung KS, Kim SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011). J Hepatol. 2015;63(2):486–93. https://doi.org/10.1016/j.jhep.2015.02.051.

    Article  Google Scholar 

  23. Lee YH, Kim SU, Song K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). Hepatology. 2016;63(3):776–86. https://doi.org/10.1002/hep.28376.

    Article  CAS  Google Scholar 

  24. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyere O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One. 2017;12(1):e0169548. https://doi.org/10.1371/journal.pone.0169548.

    Article  CAS  Google Scholar 

  25. Gao Q, Mei F, Shang Y, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr. 2021;40(7):4633–41. https://doi.org/10.1016/j.clnu.2021.06.009.

    Article  Google Scholar 

  26. Tyrovolas S, Koyanagi A, Olaya B, et al. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. J Cachexia Sarcopenia Muscle. 2016;7(3):312–21. https://doi.org/10.1002/jcsm.12076.

    Article  Google Scholar 

  27. Baker JF, Harris T, Rapoport A, et al. Validation of a description of sarcopenic obesity defined as excess adiposity and low lean mass relative to adiposity. J Cachexia Sarcopenia Muscle. 2020;11(6):1580–9. https://doi.org/10.1002/jcsm.12613.

    Article  Google Scholar 

  28. Batsis JA, Mackenzie TA, Lopez-Jimenez F, Bartels SJ. Sarcopenia, sarcopenic obesity, and functional impairments in older adults: National Health and nutrition examination surveys 1999-2004. Nutr Res. 2015;35(12):1031–9. https://doi.org/10.1016/j.nutres.2015.09.003.

    Article  CAS  Google Scholar 

  29. Du K, Goates S, Arensberg MB, Pereira S, Gaillard T. Prevalence of sarcopenia and sarcopenic obesity vary with race/ethnicity and advancing age. Divers Equal Health Care. 2018;15(4):175–83.

    Article  Google Scholar 

  30. Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Association between sarcopenic obesity and nonalcoholic fatty liver disease and fibrosis detected by Fibroscan. J Gastrointestin Liver Dis. 2021;30(2):227–32. https://doi.org/10.15403/jgld-3323.

    Article  Google Scholar 

  31. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513–37. https://doi.org/10.1038/s41574-018-0062-9.

    Article  Google Scholar 

  32. Barazzoni R, Bischoff S, Boirie Y, et al. Sarcopenic obesity: time to meet the challenge. Obes Facts. 2018;11(4):294–305. https://doi.org/10.1159/000490361.

    Article  Google Scholar 

  33. Centers for Disease Control and Prevention National Health and Nutrition Examination Survey: Methods and Analytic Guidelines. https://wwwn.cdc.gov/nchs/nhanes/analyticguidelines.aspx. Accessed 17 Jan 2022

  34. Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–58. https://doi.org/10.1093/gerona/glu010.

    Article  Google Scholar 

  35. Cawthon PM, Peters KW, Shardell MD, et al. Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014;69(5):567–75. https://doi.org/10.1093/gerona/glu023.

    Article  Google Scholar 

  36. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical Care of Patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203. https://doi.org/10.4158/EP161365.GL.

    Article  Google Scholar 

  37. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62. https://doi.org/10.1210/jc.2014-3415.

    Article  CAS  Google Scholar 

  38. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38. https://doi.org/10.1161/01.cir.0000437739.71477.ee.

    Article  Google Scholar 

  39. Koopman RJ, Mainous AG 3rd, Diaz VA, Geesey ME. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med. 2005;3(1):60–3. https://doi.org/10.1370/afm.214.

    Article  Google Scholar 

  40. Centers for Disease Control and Prevention NHANES 1999-2006 DXA multiple imputation data files. https://wwwn.cdc.gov/nchs/nhanes/dxa/dxa.aspx. Accessed 10 Feb 2022

  41. Levine ME, Crimmins EM. The impact of insulin resistance and inflammation on the association between sarcopenic obesity and physical functioning. Obesity (Silver Spring). 2012;20(10):2101–6. https://doi.org/10.1038/oby.2012.20.

    Article  CAS  Google Scholar 

  42. Yasuoka M, Muraki I, Imano H, et al. Joint impact of muscle mass and waist circumference on type 2 diabetes in Japanese middle-aged adults: The Circulatory Risk in Communities Study (CIRCS). J Diabetes. 2020;12(9):677–85. https://doi.org/10.1111/1753-0407.13049.

    Article  CAS  Google Scholar 

  43. Son JW, Lee SS, Kim SR, et al. Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES. Diabetologia. 2017;60(5):865–72. https://doi.org/10.1007/s00125-016-4196-9.

    Article  Google Scholar 

  44. Bellafronte NT, de Queiros Mattoso Ono A, Chiarello PG. Sarcopenic obesity in chronic kidney disease: challenges in diagnosis using different diagnostic criteria. Med Princ Pract. 2021;30(5):477–86. https://doi.org/10.1159/000517597.

    Article  Google Scholar 

  45. Dierkes J, Dahl H, Lervaag Welland N, et al. High rates of central obesity and sarcopenia in CKD irrespective of renal replacement therapy - an observational cross-sectional study. BMC Nephrol. 2018;19(1):259. https://doi.org/10.1186/s12882-018-1055-6.

    Article  CAS  Google Scholar 

  46. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56(4):1010–3. https://doi.org/10.2337/db06-1656.

    Article  CAS  Google Scholar 

  47. Waters DL, Qualls CR, Dorin RI, Veldhuis JD, Baumgartner RN. Altered growth hormone, cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body composition phenotypes. J Gerontol A Biol Sci Med Sci. 2008;63(5):536–41. https://doi.org/10.1093/gerona/63.5.536.

    Article  Google Scholar 

  48. Abbatecola AM, Ferrucci L, Ceda G, et al. Insulin resistance and muscle strength in older persons. J Gerontol A Biol Sci Med Sci. 2005;60(10):1278–82. https://doi.org/10.1093/gerona/60.10.1278.

    Article  Google Scholar 

  49. Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457. https://doi.org/10.1001/jamanetworkopen.2020.33457.

    Article  Google Scholar 

  50. Li R, Xia J, Zhang XI, et al. Associations of muscle mass and strength with all-cause mortality among US older adults. Med Sci Sports Exerc. 2018;50(3):458–67. https://doi.org/10.1249/MSS.0000000000001448.

    Article  Google Scholar 

  51. White DK, Neogi T, Nevitt MC, et al. Trajectories of gait speed predict mortality in well-functioning older adults: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci. 2013;68(4):456–64. https://doi.org/10.1093/gerona/gls197.

    Article  Google Scholar 

  52. Schutzer KA, Graves BS. Barriers and motivations to exercise in older adults. Prev Med. 2004;39(5):1056–61. https://doi.org/10.1016/j.ypmed.2004.04.003.

    Article  Google Scholar 

  53. McLean RR, Shardell MD, Alley DE, et al. Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project. J Gerontol A Biol Sci Med Sci. 2014;69(5):576–83. https://doi.org/10.1093/gerona/glu012.

    Article  Google Scholar 

  54. Nezameddin R, Itani L, Kreidieh D, et al. Understanding sarcopenic obesity in terms of definition and health consequences: a clinical review. Curr Diabetes Rev. 2020;16(9):957–61. https://doi.org/10.2174/1573399816666200109091449.

    Article  Google Scholar 

Download references

Acknowledgements

Medical writing support, under the direction of the authors, was provided by Caroline Ridley, PhD, Prime, Knutsford, UK, supported by Regeneron Pharmaceuticals, Inc., according to Good Publication Practice guidelines (Link). The sponsor was involved in the study design and collection, analysis, and interpretation of data, as well as data checking of information provided in the manuscript. The authors were responsible for all content and editorial decisions, and received no honoraria related to the development of this publication.

Funding

The study was funded by Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. All authors are employees of the funder.

Author information

Authors and Affiliations

  1. Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6707, USA

    Dana J. Murdock, Ning Wu, Joseph S. Grimsby, Roberto A. Calle, Stephen Donahue, David J. Glass, Mark W. Sleeman & Robert J. Sanchez

Authors
  1. Dana J. Murdock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ning Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph S. Grimsby
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto A. Calle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephen Donahue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David J. Glass
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mark W. Sleeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert J. Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DJM, NW, and RJS designed the study. DJM, NW, JSG, RAC, SD, DJG, MWS, and RJS analyzed and interpreted the data. The manuscript draft was written/revised by all authors. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Robert J. Sanchez.

Ethics declarations

Ethics approval and consent to participate

The local Institutional Review Board exempted this study due to the de-identified nature of the data.

Consent for publication

Not applicable.

Competing interests

All authors are employees and stockholders of Regeneron Pharmaceuticals, Inc.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Supplemental Table S1. Criteria of clinical subgroups. Supplemental Table S2. Model beta values for participants aged ≥ 60 years. Supplemental Table S3. Patient characteristics based on ALM and percentage BF. Supplemental Table S4. Functional characteristics of participants by age, with and without OLLMM (based on percentage BF). Supplemental Figure S1. Fitted logistic regression model on 70% training sample for OLLMM in (A) males aged ≥ 60 years, and (B) females aged ≥ 60 years. Supplemental Figure S2. Performance of selected logistic regression models in 1999–2006 NHANES data, 70% training sample for (A) males aged ≥ 60 years, and (B) females aged ≥ 60 years. Supplemental Figure S3. Overall prevalence of OLLMM in the USA identified during 2017–2018 based on BMI ≥ 27 kg/m2.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Murdock, D.J., Wu, N., Grimsby, J.S. et al. The prevalence of low muscle mass associated with obesity in the USA. Skeletal Muscle 12, 26 (2022). https://doi.org/10.1186/s13395-022-00309-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13395-022-00309-5

Keywords

  • Sarcopenic obesity
  • Sarcopenia
  • Prevalence
  • Body mass index
  • Atrophy
  • Muscle loss

Skeletal Muscle

ISSN: 2044-5040

Contact us